Oncology Preclinical Deal Benchmarks — Ex-US (2026)
Median upfront of $15M with total deal values reaching $363M in Ex-US territory.
Median Upfront
$15M
Total Deal Value
$227M
Royalty Range
4.2%–8.4%
Territory Multiplier
0.45x
Understanding Oncology Deal Benchmarks at Preclinical
Preclinical Oncology licensing deals in Ex-US territory command a median upfront payment of $15M, with values ranging from $5M at the low end to $25M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the oncology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Full Benchmark Data
Full Benchmark Table
Low, median, and high ranges for upfront payments, total deal values, and royalty rates.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Comparable Deals
See All Comparable Deals
View 10 comparable Oncology transactions with upfront payments, total values, and deal structures.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Preclinical Oncology deals in Ex-US territory?
More Expert Insights
Territory impact analysis, royalty negotiation strategies, and deal structure guidance.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Related Benchmarks
$40M upfront
Oncology · Phase 1 · Ex-US
$116M upfront
Oncology · Phase 2 · Ex-US
$324M upfront
Oncology · Phase 3 · Ex-US
$934M upfront
Oncology · Approved · Ex-US
$15M upfront
Neurology/CNS · Preclinical · Ex-US
$32M upfront
Immunology · Preclinical · Ex-US
$35M upfront
Metabolic/Obesity · Preclinical · Ex-US
$32M upfront
Oncology · Preclinical · Global
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open Deal CalculatorCite This Data
Ambrosia Ventures. (2026). Oncology Preclinical Deal Benchmarks — Ex-US (2026). Retrieved from https://calculator.ambrosiaventures.co/data/oncology-preclinical-deals-ex-us
<a href="https://calculator.ambrosiaventures.co/data/oncology-preclinical-deals-ex-us">Oncology Preclinical Deal Benchmarks — Ex-US (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://calculator.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=oncology&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,900+ verified biopharma transactions. Updated monthly.